![Fig. 7. In vivo tracking of BCL1 tumor in peritoneal cavity. / HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and throughout the course of therapy. Mice were then inoculated with 107BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse total). One animal per group was killed each day of therapy, and the percentage tumor cells in the peritoneum was analyzed using 2-color flow cytometry with PE-labeled anti-Id and FITC-labeled anti-CD22. In mice treated with [huCD64 × Id] BsAb, tumor cells were detected using FITC-labeled anti-CD22 and PE-labeled anti-CD19 (see “Materials and methods”). The graph shows the percentage of tumor cells in the peritoneal cavity present on each day of therapy after treatment with PBS (●), [huCD64 × Id] BsAb (○), [huCD64 × MHC II] BsAb (■), or [huCD64 × CD19] BsAb (▵). Symbols on plots show BsAb specificity. The inset shows scatter profiles of tumor (gated) on day 5, from mice receiving control PBS (top) or anti-MHC II BsAb (bottom). Similar results were obtained in at least 2 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347007.jpeg?Expires=1735514394&Signature=28h3NclInMsiAjs4wd9q6OptUJ-AUSNwMev5sD2PL8kwtmYF0BikEAcI6JF~uhQ2h2C5fSUaT6z67RBvJ5HtmZ4xiFpvn2HHh0rzgu9JZwEj8YZhHg7FtJWA0FOeILMD4gnanNedb89P-dJRdMAUZLWkqEJEcWs4Y5n3naBvNXv38Lr~H1WnoZqiCwYW0ZAylaTTX3GeElhX5WdsTIIH8MoM5UXVbfs2vsvrX9ytEOVQjIPJzE5wbyYDJr2Z~1KePLJNKcB0hqP1jWmjcvIBDXxZkAvd-olWDWn8tXf0jxyWkL9fVWExQreE9ia-JvrC8Rvq0la7qZlyVzvAT4sH4g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vivo tracking of BCL1 tumor in peritoneal cavity.
HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and throughout the course of therapy. Mice were then inoculated with 107BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse total). One animal per group was killed each day of therapy, and the percentage tumor cells in the peritoneum was analyzed using 2-color flow cytometry with PE-labeled anti-Id and FITC-labeled anti-CD22. In mice treated with [huCD64 × Id] BsAb, tumor cells were detected using FITC-labeled anti-CD22 and PE-labeled anti-CD19 (see “Materials and methods”). The graph shows the percentage of tumor cells in the peritoneal cavity present on each day of therapy after treatment with PBS (●), [huCD64 × Id] BsAb (○), [huCD64 × MHC II] BsAb (■), or [huCD64 × CD19] BsAb (▵). Symbols on plots show BsAb specificity. The inset shows scatter profiles of tumor (gated) on day 5, from mice receiving control PBS (top) or anti-MHC II BsAb (bottom). Similar results were obtained in at least 2 similar experiments.
